DE4038692A1 - Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc. - Google Patents
Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc.Info
- Publication number
- DE4038692A1 DE4038692A1 DE19904038692 DE4038692A DE4038692A1 DE 4038692 A1 DE4038692 A1 DE 4038692A1 DE 19904038692 DE19904038692 DE 19904038692 DE 4038692 A DE4038692 A DE 4038692A DE 4038692 A1 DE4038692 A1 DE 4038692A1
- Authority
- DE
- Germany
- Prior art keywords
- esp
- basic substance
- vol
- urea
- glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 239000000126 substance Substances 0.000 title claims abstract description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000004202 carbamide Substances 0.000 title claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 14
- 208000030533 eye disease Diseases 0.000 title claims abstract description 13
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 235000021120 animal protein Nutrition 0.000 title claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 239000000419 plant extract Substances 0.000 title claims abstract description 5
- 108010064851 Plant Proteins Proteins 0.000 title 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 5
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 5
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 5
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 5
- 229940036350 bisabolol Drugs 0.000 claims abstract description 5
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 5
- 239000004310 lactic acid Substances 0.000 claims abstract description 5
- 241000086254 Arnica montana Species 0.000 claims abstract description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 3
- 150000003893 lactate salts Chemical class 0.000 claims abstract description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract 6
- 208000002177 Cataract Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 6
- 244000144927 Aloe barbadensis Species 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 241000208680 Hamamelis mollis Species 0.000 claims description 2
- 229920000289 Polyquaternium Polymers 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 229940118846 witch hazel Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000012676 herbal extract Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 244000186892 Aloe vera Species 0.000 abstract 1
- 241000208690 Hamamelis Species 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 235000013877 carbamide Nutrition 0.000 description 9
- 241000219739 Lens Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- -1 imidazolidinyl urea Chemical compound 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000019704 lentil protein Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Die Erfindung betrifft ein Mittel zur Behandlung von Augenerkrankungen, insbesondere von grauem Star od. dgl. Linsentrübungen.The invention relates to an agent for the treatment of Eye diseases, especially cataracts or the like Lens opacification.
Eine verbreitete Augenkrankheit ist der graue Star, der als Linsentrübung oder Katarakt bezeichnet wird. Die Pupille erscheint grau. Das Linsengewebe verändert sich, es wird in eine milchige Masse verwandelt und verkalkt allmählich. Hierbei kann es sogar zu einer Tagblindheit kommen. Der graue Star tritt vor allem im Alter auf, bei der Zuckerkrankheit, bei Tetanie, bei Ausfall der Nebenschilddrüsen, bei einer bestimmten degenerativen Muskelerkrankung oder auch nach Ver letzungen und Vergiftungen. A common eye disease is cataracts is called lens opacification or cataract. The The pupil appears gray. The lens tissue changed itself, it is turned into a milky mass and gradually calcifies. This can even lead to a Day blindness is coming. The cataract occurs especially in the Age on, on diabetes, on tetany, on Failure of the parathyroid glands, at a certain degenerative muscle disease or after ver injuries and poisoning.
Ferner kann es durch starke Hitzeeinwirkung oder auch durch Radium- und Röntgenstrahlen zum grauen Star kommen.It can also be caused by intense heat or through radium and x-rays to cataracts come.
Bis heute wird der graue Star durch innerliche Jodgaben, mit Hormon-Präparaten und mit Linseneiweiß behandelt. Die einzige Möglichkeit aber, Blinde wieder sehend zu machen, ist die Operation. Hierbei wird die Linse im ganzen entfernt.To this day, cataracts are caused by internal Iodine administration, with hormone preparations and with lentil protein treated. The only way, however, is blind again to make seeing is the operation. Here, the Lens removed throughout.
Es sind aber auch andere Augenerkrankungen bekannt, wie beispielsweise die Conjunctivitis (Bindehautentzün dung), wobei hier das Augenweiß gerötet erscheint. Ferner kommt es auch auf anderem Wege als durch den grauen Star zu einer Hornhauttrübung, wobei all diese Augenerkrankungen nur mit speziellen Mitteln behandelt werden können, die allesamt jedoch nicht sehr wirkungsvoll sind.But there are also other eye diseases known, such as for example conjunctivitis (conjunctivitis dung), whereby the whites of the eyes appear red here. It also happens in a different way than through the cataracts to corneal opacity, taking all of these Eye diseases only treated with special agents can be, but not all are effective.
Der Erfinder hat sich zum Ziel gesetzt, ein Mittel der o.g. Art zu entwickeln, welches bei vielen Augener krankungen einsetzbar ist und welches die Sehkraft zumindest teilweise und kurzfristig wieder herstellt.The inventor set himself the goal of being a means of o.g. Way to develop, which in many eyes diseases can be used and what the eyesight restores at least partially and at short notice.
Zur Lösung dieser Aufgabe führt, daß eine Grundsubstanz zum Aufbringen auf das Auge, insbesondere deminerali siertes, sterilisiertes Wasser, einen Harnstoff (Urea) enthält.A basic substance leads to the solution of this task for application to the eye, especially deminerali sterilized water, a urea (urea) contains.
Harnstoff ist das Diamid der Kohlensäure und ist heute auf synthetischem Wege herstellbar. Urea is the diamide of carbonic acid and is today Can be produced synthetically.
Es findet bereits in Arzneimitteln oder beispielsweise auch in Schlafmitteln Anwendung. Im menschlichen Körper selbst ist Harnstoff ein wichtiges Endprodukt des Eiweißstoffwechsels. Der Harnstoff hat die Fähigkeit in beispielsweise die Linse einzudringen und dort einer Trübung entgegenzuwirken. Hierbei reduziert er die milchige Masse, so daß die Sehkraft gestärkt wird. Vermutlich ist dies auf eine denaturierende Wirkung des Harnstoffes auf zelluläre Proteine zurückzuführen.It is already found in drugs or for example also used in sleeping pills. In the human body itself is an important end product of the Protein metabolism. The urea has the ability in for example to penetrate the lens and there one Counteract turbidity. Here he reduces the milky mass, so that the eyesight is strengthened. This is probably due to a denaturing effect of the Attributed to cellular proteins.
Bevorzugt enthält die Grundsubstanz aus dem Harnstoff noch ein Glykol. Allerdings hat sich auch erwiesen, daß der Harnstoff bei Zugabe von Glykol wesentlich vermindert werden kann, so daß zu erwarten ist, daß auch ein Mittel mit Glykol alleine bereits die oben beschriebenen vorteilhaften Wirkungen hat. Bekannt ist die Verwendung von beispielsweise Glykoläther als Weichmacher und Lösemittel. Im vorliegenden Fall hat sich herausgestellt, daß das Glykol ohne Schädigung der Linse in diese eindringt und dort die Linsentrübung auflöst. Ähnliches geschieht auch bei einer Hornhaut trübung.The base substance preferably contains urea another glycol. However, it has also been shown that the urea is essential when adding glycol can be reduced, so that it can be expected that also an agent with glycol alone the above described beneficial effects. Is known the use of, for example, glycol ether Plasticizers and solvents. In the present case it turned out that the glycol without damaging the Lens penetrates into this and there the lens opacity dissolves. The same happens with a cornea cloudiness.
Weiterhin besteht die Möglichkeit, daß die Grundsubstanz tierische Proteine, insbesondere hydrolysierte tierische Proteine enthält. Diese haben den Vorteil, daß sie beruhigend auf einen lokalen Applikationsort wirken, so daß hierdurch, falls auch andere der o.g. Stoffe in der Grundsubstanz enthalten sind, beispielsweise ein Eindringen von Harnstoffen oder Glykol in die Linse erleichtert wird, da die Linsenoberfläche entspannt bleibt. There is also the possibility that the Basic substance animal proteins, in particular contains hydrolyzed animal proteins. Have this the advantage of being reassuring to a local Application site act, so that this, if also other of the above Contain substances in the basic substance are, for example, penetration of ureas or glycol in the lens is eased because the Lens surface remains relaxed.
Eine ähnliche Wirkung haben auch pflanzliche Extrakte, insbesondere Hamamelis, Arnika und Minze.Plant extracts have a similar effect, especially witch hazel, arnica and mint.
Auch ein Zusatz von Milchsäure bzw. von Lactaten sowie Aloe Vera Gel, Methylparabene, PCA (2-Pyolydon-5-Carbonsäure) und Bisabolol wirkt sich entweder günstig auf die Verbesserung der Sehkraft aus oder aber sollte zugegeben werden, um das Mittel selbst haltbarer und geeigneter für die Aufnahme im Auge zu machen.The addition of lactic acid or lactates as well as aloe vera gel, methyl parabens, PCA ( 2- pyolydone-5-carboxylic acid) and bisabolol either have a positive effect on the improvement of the eyesight or should be added to make the product itself more durable and more suitable for taking in the eye.
In einer bevorzugten Ausführungsform enthält das Mittel folgende Zusammensetzung:In a preferred embodiment, the agent contains following composition:
68-85 Vol.-% demineralisiertes, sterilisiertes Wasser
0,3-1,2 Vol.-% Harnstoff und/oder
0,2-1,0 Vol.-% tierische Proteine und/oder
0,3-1,2 Vol.-% Pflanzenextrakte und/oder
6-15 Vol.-% Glykol und/oder
0,2-0,3 Vol.-% Milchsäure und/oder
-1,0 Vol.-% Aloe Vera Gel und/oder
-0,2 Vol.-% Methylparaben und/oder
-0,1 Vol.-% PCA und/oder
-0,1 Vol.-% Bisabolol enthält.68-85% by volume of demineralized, sterilized water
0.3-1.2% by volume of urea and / or
0.2-1.0% by volume of animal proteins and / or
0.3-1.2% by volume of plant extracts and / or
6-15 vol .-% glycol and / or
0.2-0.3% by volume lactic acid and / or
-1.0 vol .-% aloe vera gel and / or
-0.2 vol .-% methyl paraben and / or
-0.1 vol% PCA and / or
Contains -0.1 vol .-% bisabolol.
Zusätzlich zu diesen Stoffen oder einem dieser Stoffe hat sich eine Zugabe von einem speziellen Harnstoff, nämlich Imidazolidinyl Urea, als sehr wirkungssteigernd erwiesen. Auch ein weiterer Zusatz von Hydroxypopyl Methylzellulose, Aminosäure oder Polyquaternium verbessert die Wirkung des Mittels.In addition to these substances or one of these substances has an addition of a special urea, namely imidazolidinyl urea, as a very effective enhancer proven. Another addition of hydroxypopyl Methyl cellulose, amino acid or polyquaternium improves the effect of the remedy.
Im übrigen ist das Mittel auch besonders bei erhöhtem Augeninnendruck und Durchblutungsstörungen einsetzbar.For the rest, the remedy is also particularly high Intraocular pressure and circulatory disorders can be used.
Claims (13)
0,3-1,2 Vol.-% Harnstoff und/oder
0,2-1,0 Vol.-% tierische Proteine und/oder
0,3-1,2 Vol.-% Pflanzenextrakte
6-15 Vol.-% Glykol und/oder
0,2-0,3 Vol.-% Milchsäure und/oder
-1,0 Vol.-% Aloe Vera Gel und/oder
-0,2 Vol.-% Methylparaben und/oder
-0,1 Vol.-% PCA und/oder
-0,1 Vol.-% Bisabolol enthält.9. Composition according to at least one of claims 1 to 8, characterized in that the basic substance from 68-85 vol .-% demineralized, sterilized water additionally
0.3-1.2% by volume of urea and / or
0.2-1.0% by volume of animal proteins and / or
0.3-1.2 vol% plant extracts
6-15 vol .-% glycol and / or
0.2-0.3% by volume lactic acid and / or
-1.0 vol .-% aloe vera gel and / or
-0.2 vol .-% methyl paraben and / or
-0.1 vol% PCA and / or
Contains -0.1 vol .-% bisabolol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904038692 DE4038692A1 (en) | 1990-12-05 | 1990-12-05 | Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904038692 DE4038692A1 (en) | 1990-12-05 | 1990-12-05 | Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE4038692A1 true DE4038692A1 (en) | 1992-06-11 |
Family
ID=6419578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19904038692 Withdrawn DE4038692A1 (en) | 1990-12-05 | 1990-12-05 | Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc. |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4038692A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0646641A3 (en) * | 1993-10-01 | 1996-04-10 | Senju Pharma Co | Method of stabilizing preparation for contact lenses. |
| WO2000009105A3 (en) * | 1998-08-14 | 2000-06-02 | Guilford Pharm Inc | Small molecule carbamates or ureas for vision and memory disorders |
| WO2006068899A3 (en) * | 2004-12-22 | 2007-01-25 | Bausch & Lomb | Preserved ophthalmic compositions comprising aloe vera |
| LT6293B (en) | 2015-11-05 | 2016-08-10 | Uab "Origmed" | Pharmaceutical preparation for eyes with propolis and aloe vera and method of preparation thereof |
-
1990
- 1990-12-05 DE DE19904038692 patent/DE4038692A1/en not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0646641A3 (en) * | 1993-10-01 | 1996-04-10 | Senju Pharma Co | Method of stabilizing preparation for contact lenses. |
| US5571504A (en) * | 1993-10-01 | 1996-11-05 | Senju Pharmaceutical Co., Ltd. | Method of stabilizing preparations for contact lenses |
| WO2000009105A3 (en) * | 1998-08-14 | 2000-06-02 | Guilford Pharm Inc | Small molecule carbamates or ureas for vision and memory disorders |
| WO2006068899A3 (en) * | 2004-12-22 | 2007-01-25 | Bausch & Lomb | Preserved ophthalmic compositions comprising aloe vera |
| LT6293B (en) | 2015-11-05 | 2016-08-10 | Uab "Origmed" | Pharmaceutical preparation for eyes with propolis and aloe vera and method of preparation thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69429522T2 (en) | INJECTABLE COMPOSITIONS TO ENLARGE SOFT TISSUE | |
| DE3125260C2 (en) | Water-containing, viscoelastic mixture containing hyaluronate and cosmetic products containing these mixtures | |
| EP0254289B1 (en) | Agent for the treatment of arthrosis | |
| DE69230242T2 (en) | Process for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use. | |
| EP0340592B2 (en) | Hair treatment composition with natural ingredients | |
| CH637018A5 (en) | AGENT FOR IMPROVING CIRCULATION AND Wounds Healing. | |
| DE10161149B4 (en) | Use of heparin-containing ophthalmic agent | |
| DE2658237A1 (en) | MEDICINAL PRODUCTS FOR INJECTION INTO THE SPINAL DISCS TO RELIEVE BACK PAIN AND OTHER UNWANTED SYMPTOMS | |
| DE69402826T2 (en) | COMPOSITION FOR HAIR CARE | |
| DE4038692A1 (en) | Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc. | |
| EP2996710A1 (en) | Active substance for treating sarcopenia | |
| DE2719770C3 (en) | Use of coagens in the manufacture of ophthalmic pharmaceutical compositions with slow release properties | |
| DE2153386B2 (en) | HAIR CARE PRODUCTS, CONTAINS LAB | |
| DE19520575A1 (en) | Spray or gel compsn. contg. hyaluronic acid and heparin | |
| DE4310974C2 (en) | Use of hydroxyethyl starch to improve microcirculation | |
| DE2117057C3 (en) | Process for the manufacture of a medicament for the treatment of eye diseases | |
| DE10251753B4 (en) | Agent for the treatment of pain and inflammation in the horse, especially in joints | |
| DE1667890B2 (en) | DERMATOLOGICAL AND COSMETIC EXTERNAL PRODUCTS FOR THE TREATMENT OF SKIN COLLAGENOSE | |
| US4778828A (en) | Method and composition for treating cataracts | |
| DE3901575C2 (en) | ||
| EP1455806B1 (en) | Active agent mixture containing a plant extract of convolvulaceae for treating hair problems, skin disorders and skin diseases | |
| DE19747195A1 (en) | Compositions for treating diabetic retinopathy | |
| DE3605570C1 (en) | Composition for tightening areas of human skin | |
| DE1492075B2 (en) | Cosmetic agent for assisting the treatment of hair loss and / or seborrhea, as well as processes for the production thereof | |
| AT310350B (en) | Process for obtaining an eye extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |